Diagnosis and Treatment of Tuberculous Meningitis

Tuberculous meningitis (TBM) arises when Mycobacterium tuberculosis disseminates to the meninges, provoking an intense inflammatory response that can lead to raised intracranial pressure, hydrocephalus and cerebral infarction. Early clinical suspicion hinges on subacute headaches, fever, altered mentation and focal neurological signs. Definitive diagnosis requires analysis of cerebrospinal fluid (CSF) obtained by lumbar puncture, with evaluation of cell count, protein and glucose, supplemented by neuroimaging to detect meningeal enhancement, infarcts or ventricular dilatation. Conventional microbiological confirmation remains insensitive, prompting adoption of rapid molecular assays. Treatment mirrors pulmonary tuberculosis regimens but must account for drug penetration into the CSF. High-dose rifampicin, isoniazid, pyrazinamide and ethambutol form the core four-drug induction phase, followed by continuation therapy. Adjunctive corticosteroids reduce mortality in HIV-negative individuals, while host-directed therapies such as aspirin and linezolid are under evaluation. Management of complications—raised intracranial pressure, hydrocephalus and vascular events—requires neurosurgical and critical care interventions. Despite advances, delays in diagnosis and suboptimal drug dosing contribute to high mortality and morbidity, highlighting an urgent need for sensitive diagnostics, optimised pharmacotherapy and tailored supportive care.

Research from Nature Portfolio

Transcriptomic profiling of paired blood and ventricular versus lumbar CSF samples in paediatric TBM has revealed compartmentalised immune signatures. Peripheral blood showed upregulation of both canonical and non-canonical inflammasome pathways alongside T-cell suppression. Ventricular CSF exhibited enrichment of genes associated with neuronal excitotoxicity and cerebral injury, whereas lumbar CSF reflected protein translation and cytokine signalling networks. These findings underscore the heterogeneity of host responses across CNS compartments and suggest that site-specific markers could guide precision diagnostics and novel host-directed interventions.

Diagnosis and Treatment of Tuberculous Meningitis publication trend

The graph below shows the total number of articles in diagnosis and treatment of tuberculous meningitis across all publications each year (not limited to Nature Index journals).

Technical terms

Cerebrospinal fluid (CSF): The clear fluid surrounding the brain and spinal cord, analysed to detect infection or inflammation.

Blood–brain barrier (BBB): A selective vascular interface that limits entry of pathogens and drugs into the central nervous system.

GeneXpert MTB/RIF: A cartridge-based nucleic acid amplification test that rapidly detects M. tuberculosis and rifampicin resistance in CSF.

Hydrocephalus: Accumulation of CSF within ventricles leading to increased intracranial pressure, often requiring surgical diversion.

Adjunctive therapy: Treatment given in addition to standard antimicrobial regimens to modulate host inflammation or prevent complications.

References

1. Distinctive antibody responses to Mycobacterium tuberculosis in pulmonary and brain infection. Brain (2024).
2. The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes. Wellcome Open Research (2019).
3. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. eLife (2018).
4. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. Clinical Infectious Diseases (2019).
5. Treatment of Tuberculous Meningitis and Its Complications in Adults. Current Treatment Options in Neurology (2018).
6. Tuberculous meningitis: where to from here?. Current Opinion in Infectious Diseases (2020).
7. Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity. Nature Communications (2019).